Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.

MLA

Saraux, Alain, et al. “Early Non-Response to Certolizumab Pegol in Rheumatoid Arthritis Predicts Failure to Achieve Low Disease Activity at 1 Year: Data from a Prospective Observational Study.” RMD Open, vol. 6, no. 1, Jan. 2020. EBSCOhost, https://doi.org/10.1136/rmdopen-2019-000991.

APA

Saraux, A., Flipo, R.-M., Fagnani, F., Massol, J., Cukierman, G., Joubert, J.-M., Huot-Marchand, P., & Combe, B. (2020). Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. RMD Open, 6(1). https://doi.org/10.1136/rmdopen-2019-000991

Chicago

Saraux, Alain, René-Marc Flipo, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand, and Bernard Combe. 2020. “Early Non-Response to Certolizumab Pegol in Rheumatoid Arthritis Predicts Failure to Achieve Low Disease Activity at 1 Year: Data from a Prospective Observational Study.” RMD Open 6 (1). doi:10.1136/rmdopen-2019-000991.